"gadobenate dimeglumine (Gd-BOPTA): weak and transient protein bonding ("
"gadoxetate disodium (Gd-EOB-DTPA): has protein binding of"
"gadobenate dimeglumine (Gd-BOPTA): weak and transient protein bonding ("
"gadobenate dimeglumine (Gd-BOPTA): weak and transient protein bonding ("
"gadoxetate disodium (Gd-EOB-DTPA): has protein binding of"
"particle size of 50 to 180 nm with a thin, incomplete dextran coating that causes individual particles to form polycrystalline aggregates. These aggregates behave in solutions or within cells as large particles."
"Hepatobiliary specific gadolinium agents include two of the high relaxivity agents: gadobenate dimeglumine (Gd-BOPTA) and gadoxetate disodium (Gd-EOB-DTPA)."
"gadobenate dimeglumine (Gd-BOPTA): weak and transient protein bonding ("
"T2-weighted FS fast SE"
"T2-weighted FS fast SE"
"parenchymal assessment: axial and/or coronal 2D or 3D T1-weighted FS spoiled GRE"
"functional MRCP: axial and oblique coronal 2D or 3D T1-weighted FS GRE"
"Preferred MR protocol"
Expected headings
"Gadolinium-based agents"
"Manganese-based agents"
"Disadvantages"
"Superparamagnetic iron oxide particles"
"Preferred MR protocol"
"Precontrast imaging"
"Post contrast imaging"
"Mangafodipir trisodium (Mn-DPDP) is specifically taken up by hepatocytes due to its chemical similarity to vitamin B6. This property results in the increase in signal intensity of normal hepatic parenchyma. Thus, in the presence of a focal liver lesion, the increased signal of normal parenchyma gives a high lesion-to-liver contrast and hence provides improved detection, characterisation and evaluation of liver lesions."
"liver appears darkest on T2*/T2 weighted images in the first 24 hours post infusion. The liver signal intensity returns to normal within 7 to 14 days in most cases; however, complete metabolism requires 14 to 28 days"